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Background: Non-invasive models and methods to substitute liver biopsy in chronic hepatitis B (CHB) patients
were investigated but their roles as predictors of significant liver histology for diagnosis of HBeAg-negative CHB
patients who had indication for liver biopsy according to The American Association for the Study of Liver Diseases
(AASLD) and The Asian Pacific Association for the Study of the Liver (APASL) guidelines are still unknown. This study
was designed to identify predictors of significant liver necroinflammation as defined by a Histology Activity Index of
necroinflammatory score ≥ 4 or Metavir necroinflammatory activity score ≥ 2 and significant liver fibrosis as defined
by a Metavir fibrosis score ≥ 2 in HBeAg-negative CHB patients that had a hepatitis B virus (HBV) DNA level ≥
2,000 IU/ml and age≥ 40 years or elevated alanine aminotransferase level between 1–2 times the upper limit of normal.
Methods: Twenty-two patients were prospectively included and performed liver biopsies. Clinical and laboratory
parameters including age, gender, underlying disease, family history of cirrhosis or hepatocellular carcinoma, body mass
index (BMI), HBV DNA level, HBsAg level, liver function test, complete blood count, aspartate aminotransferase-to-platelet
ratio index and transient elastography were collected and analyzed with liver histology profiles.
Results: Five patients (23%) had significant liver inflammation and 7 patients (32%) had significant liver fibrosis. Factors
associated with significant liver inflammation were a lower BMI and higher alkaline phosphatase level while a factor
associated with significant liver fibrosis was lower age. On multivariate analysis, only HBV DNA level > 5.5 log IU/ml could
predict significant liver fibrosis (odds ratio 28.012, 95% CI, 1.631-481.240, p = 0.022) and its sensitivity, specificity, positive
predictive value and negative predictive value were 71.4%, 93.3%, 83.3% and 87.5% respectively.
Conclusions: An HBV DNA level of > 5.5 log IU/ml was able to predict significant liver fibrosis for treatment of
HBeAg-negative CHB patients that had indication for liver biopsy as recommended by AASLD and APASL guidelines.
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Liver inflammation and fibrosis evaluations are important
elements of a severity assessment for treatment decisions
in the management of chronic hepatitis B (CHB) patients.
The gold standard for evaluation in grading of liver
inflammation and staging of liver fibrosis is a liver biopsy
[1-3]. However, biopsy is an invasive procedure with
minimal but significant risk of morbidity and mortality [4].* Correspondence: goodycherry@hotmail.com
1Division of Gastroenterology, Department of Medicine, Prince of Songkla
University, Songkhla, Thailand
Full list of author information is available at the end of the article
© 2014 Praneenararat et al.; licensee BioMed C
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Non-invasive models and methods including transient
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with fair accuracy [5]. However, their accuracy in
liver histology prediction of the HBeAg-negative CHB
patient subgroup, who would require a liver biopsy as
The American Association for the Study of Liver Diseases
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a prospective cross-sectional study, the clinical and
laboratory parameters that could predict liver histology in
HBeAg-negative CHB patients who required evaluation of
liver inflammation and fibrosis by liver biopsy in accordance
with AASLD and APASL guidelines which are a hepatitis B
virus (HBV) DNA level ≥ 2,000 IU/ml and age ≥ 40 years, or
an elevated alanine aminotransferase (ALT) level between
1–2 times the upper limit of normal (ULN) [1,3]. If a
predictor is found, it might become an alternative
method for liver inflammation and fibrosis assessment
in this subgroup of patients.
Methods
Patients
All CHB patients who had visited the outpatient clinic of
the Division of Gastroenterology or the NKC institute of
Gastroenterology and Hepatology, Prince of Songkla
University, Songkhla, Thailand between November 2012
and February 2014 were screened for inclusion in the study.
Inclusion criteria were age of more than 20 years, positive
HBsAg for more than 6 months, negative HBeAg, HBV
DNA ≥ 2,000 IU/ml, no previous HBV treatment and
positive indication for liver biopsy according to
AASLD and APASL guidelines [1,3] including ALT
40–79 U/L (1–2 times of ULN) or age ≥ 40 years. The
authors also added positive family history of cirrhosis or
hepatocellular carcinoma (HCC) as an additional indica-
tion for liver biopsy due to Thai national guidelines [6]
(only 1 patient biopsied by this indication was included).
Exclusion criteria were co-infection with hepatitis C virus
or human immunodeficiency virus infection, alcohol intake
of more than 20 g/day, cirrhosis as documented by either
physical examination, laboratory or radiology findings,
HCC, pregnancy, contraindication to liver biopsy including
the presence of ascites, an international normalized ratio
over 1.5, activated partial thromboplastin time > 1.5 times
or platelets < 100,000/ml [4] and refusal to participate in
the study. Written informed consent was obtained from all
patients before enrollment. The study was approved by the
Ethical Committee of Prince of Songkla University and in
accordance with the Helsinki Declaration of 1975.
End points
The primary end point was the discovery of the factors
that may predict liver histology in HBeAg-negative CHB
patients that needed liver biopsy according to AASLD
and APASL guidelines. The secondary end points were
the associations between clinical and laboratory parameters
with liver histology.
Study design
Clinical and laboratory data for all of the eligible patients
were collected. They underwent liver stiffness (LS)measurement by TE within 2 weeks of the day of liver
biopsy. The clinical and laboratory data gathered for the
participants were age, gender, underlying disease, family
history of cirrhosis or HCC, body mass index (BMI),
HBsAg level, HBV DNA level, liver function test,
complete blood count, α-fetoprotein (AFP) and APRI.
Quantification of HBsAg and HBV DNA Levels
Serum HBsAg levels were quantified using the Architect
HBsAg QT (Abbott Laboratories) according to manu-
facturer’s instructions [7,8] with a detection range of
0.05 to 250 IU/ml. If the HBsAg level was more than
250 IU/ml, samples were diluted to 1:100 to 1:1000
to obtain a reading within the calibration curve range.
Serum HBV-DNA levels were quantified with a COBAS
AmpliPrep/COBAS TaqMan assay (Roche Diagnostic
Systems Inc, Mannheim, Germany) with a detection range
of 20–1.7×108 IU/ml.
LS measurements by TE
LS was determined using Fibroscan® (Echosens, Paris,
France) as described by Sandrin [9]. The TE operator
was a physician who had previously performed LS by
Fibroscan® on at least 50 patients (N. J.). The operators
performed at least 10 valid measurements at each time.
LS values are expressed in median (kilopascal; kPa). LS
values included in the study needed an interquartile
range of less than 30% over the median ratio and a
success rate of more than 80%.
Liver histology
Liver histology was evaluated by a pathologist (S.K.) expert
in gastroenterological pathology, blinded to any other
clinical and laboratory data and tested for intra-observer
variation. Liver samples needed to be at least 2 cm in length
and have at least 11 complete portal tracts for histological
evaluation [10]. The degrees of liver necroinflammation
were assessed against the Histology Activity Index (HAI)
necroinflammatory activity score (from 0–18) [11] and the
Metavir necroinflammatory activity score (from 0–4). The
degrees of liver fibrosis were assessed using the Metavir
fibrosis score (range 0–4) [12].
Definition
Significant liver inflammation was defined as a HAI
necroinflammatory activity score of ≥ 4 or Metavir
necroinflammatory activity score of ≥ 2, while significant
liver fibrosis was defined by a Metavir fibrosis score of ≥ 2.
If one of the above definitions were satisfied, they could
be referred to as significant liver histology. These
levels represented at least moderate inflammation and
significant fibrosis and influenced the management of
the patients in terms of treatment indications.
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The baseline characteristics were presented as means
with standard deviation. Comparison of means used
an Independent-samples t test or Mann–Whitney U
test according to data distributions. Factors that had
p-value < 0.1 were further subjected to univariate analysis
with a Fisher exact test and multivariate analysis by
multiple logistic regressions. Statistical significance was
set at p-value < 0.05.
Results
Patient characteristics
Twenty-two eligible patients were included in the study.
Baseline characteristics of all patients divided according
to liver pathology are shown in Table 1. The number of
males and females was equal, as well as positive or negative
family history of cirrhosis or HCC. The mean age of partici-
pants was 48 years. There were 4 (18%) patients with both
significant liver inflammation and fibrosis, 1 (5%) patient
with only significant inflammation and 3 (14%) patients
with significant liver fibrosis only. The indication for liver
biopsy in 4 patients under 40 years of age were elevated
ALT in 3 patients and a positive family history of cirrhosis
or HCC in 1 patient. The pathological finding in this group
resulted in significant liver fibrosis in 3 patients and both
significant liver inflammation and fibrosis in 1 patient.
The patients with significant liver inflammation
had a significantly lower BMI (22.09 ± 1.51 kg/m2 Vs
25.26 ± 3.94 kg/m2, p = 0.046) and higher alkaline
phosphatase (85.0 ± 16.7 mg/dL Vs 59.4 ± 11.7, p = 0.001)
than the patients without significant liver inflammation
while patients with significant liver fibrosis were signifi-
cantly younger (42.7 ± 8.4 years Vs 50.7 ± 8.2, p = 0.047)
than those without significant liver fibrosis. When com-
bined into the same group, the patients with significant
liver inflammation and significant liver fibrosis showed no
significant differences in baseline characteristics compared
with patients without significant liver histology.
Predictors of significant liver histology in HBeAg-negative
CHB patients
Many factors were found to predict significant liver in-
flammation in univariate analysis, including age ≤ 42 years,
BMI < 24.5 kg/m2, total bilirubin < 0.45 mg/dl, aspartate
aminotransferace > 30 mg/dl, alkaline phosphatase >
78 mg/dl, absolute neutrophil count > 4,300/mm3, cerulo-
plasmin > 20 mg/dl and LS values of ≥ 11.5 kPa (Table 2).
Nevertheless, these factors didn’t reach statistical signifi-
cance in multivariate analysis (data not shown). The same
results were also discovered in the group with significant
liver inflammation or fibrosis: a BMI of < 25 kg/m and
ALP > 78 mg/dl were associated with significant liver hist-
ology in univariate analysis, but they were not found to be
significant in the multivariate analysis (data not shown).In the group with liver fibrosis, age ≤ 42 years and HBV
DNA levels > 5.5 log IU/ml were predictors of significant
liver fibrosis in univariate analysis as a predictor of signifi-
cant liver fibrosis in univariate analysis. HBV DNA levels
> 5.5 log IU/ml was the only factor that was found as a
significant predictor from multivariate analysis [odds ratio
(OR) 28.012, 95% CI, 1.631-481.240, p = 0.022] (Table 3).
Sensitivity, specificity, positive predictive value and nega-
tive predictive value were 71.4%, 93.3%, 83.3% and 87.5%
respectively.
Discussion
In management of CHB patients, histological liver evalu-
ation is an important part of the severity assessment and
has importance for treatment decisions. Although liver
biopsy is a gold standard to determine the stage of fibrosis
and degree of necroinflammation, it is an invasive proced-
ure with minimal but significant risk of morbidity and
mortality [4]. Therefore, many non-invasive methods have
been applied to replace this invasive procedure.
With respect to liver fibrosis, the HBV DNA level was
the only factor that reached statistical significance with
an OR of 28.012 at a level of over 5.5 log IU/ml. This
finding is supported by other studies. For example, in the
study by Croagh et al. [13] HBV DNA level was found to
be a predictor of significant fibrosis in HBeAg-negative
CHB patients with varying ALT with an OR of 1.3 for
every 1 log increment [13]. Association was also found in
the study by Mohamadnejad et al. [14] with the sensitivity
of 74% and specificity of 80% at cutoff level to 4.91
log IU/ml [14]. HBV DNA levels also correlated with
advanced fibrosis in HBeAg-negative CHB patients
with normal ALT and varying ages in Xiao et al. [15]. In
contrast, this finding was not found in HBeAg-positive
CHB patients [13-16]. Further studies are necessary to
explain variable outcomes between different phases of CHB
patients. For this reason, HBV DNA level with a cut-off
value at 5.5 log IU/ml might be a promising serum marker
in predicting liver fibrosis in treatment naïve HBeAg-
negative CHB patients with positive indication for liver
biopsy as recommended by AASLD and APASL guidelines.
Younger age was another factor found to be associated
with liver fibrosis. This was against the basic knowledge
that fibrosis would progress and eventually develop into
cirrhosis with more advanced age [1-3]. This finding
might be explained by selection bias. The authors
excluded cirrhosis which could be a final outcome in
younger patients with significant histology, though
patients of more advanced age but without cirrhosis might
represent a group of patients which actually had an insig-
nificant histology. If cirrhosis was included in the present
study, the result should have been opposite.
Although LS values and APRI correlated with degree
of liver fibrosis, it was not associated with significant
Table 1 Baseline characteristics of 22 HBeAg-negative CHB patients included in the study
Parameters All patients
(N = 22)














Male/female, n (%) 11/11(50/50) - 1/4(5/18) 10/7(45/32) 0.127 4/3(18/14) 7/8(32/36) 0.647 4/7(18/32) 4/7(18/32) 1.000
Age, mean ± SD, years 48 ± 9 35 - 65 41.8 ± 8.3 50.1 ± 8.4 0.068 42.7 ± 8.4 50.7 ± 8.2 0.047 44.4 ± 9.1 50.4 ± 8.4 0.134
BMI, mean ± SD, kg/m2 24.54 ± 3.76 20.28 – 35.75 22.09 ± 1.51 25.26 ± 3.94 0.046 22.91 ± 1.64 25.30 ± 4.25 0.217 22.73 ± 1.61 25.57 ± 4.27 0.088
Positive family history of cirrhosis or HCC, n (%) 11/11(50) - 3/2(14/9) 8/9(36/41) 0.611 3/4(14/18) 8/7(36/32) 0.647 4/7(18/32) 4/7(18/32) 1.000
HBsAg levels, mean ± SD, log IU/mL 3.36 ± 0.55 1.57 – 4.24 3.01 ± 0.84 3.46 ± 0.42 0.225 3.39 ± 0.24 3.34 ± 0.66 0.698 3.16 ± 0.68 3.47 ± 0.46 0.275
HBV DNA levels, mean ± SD, log IU/mL 4.92 ± 1.21 3.59 – 7.56 5.45 ± 1.55 4.76 ± 1.09 0.327 5.63 ± 1.30 4.59 ± 1.04 0.053 5.40 ± 1.38 4.65 ± 1.05 0.172
TB, mean ± SD, mg/dL 0.55 ± 0.22 0.17 – 0.96 0.40 ± 0.11 0.60 ± 0.23 0.08 0.44 ± 0.20 0.61 ± 0.22 0.109 0.46 ± 0.19 0.61 ± 0.23 0.120
DB, mean ± SD, mg/dL 0.15 ± 0.07 0.03 – 0.29 0.13 ± 0.05 0.16 ± 0.07 0.288 0.14 ± 0.08 0.16 ± 0.06 0.458 0.14 ± 0.07 0.16 ± 0.07 0.580
AST, mean ± SD, mg/dL 30.3 ± 11.4 15 - 64 41.0 ± 16.8 27.1 ± 7.3 0.071 34.0 ± 15.8 28.5 ± 8.8 0.572 35.5 ± 15.2 27.3 ± 7.6 0.231
ALT, mean ± SD, mg/dL 35.4 ± 17.3 13 - 70 47.4 ± 21.8 31.9 ± 1.47 0.077 36.1 ± 20.1 35.1 ± 1.64 0.896 38.8 ± 20.4 33.5 ± 15.8 0.507
ALP, mean ± SD, mg/dL 65.2 ± 16.7 40 - 109 85.0 ± 16.7 59.4 ± 11.7 0.001 69.3 ± 16.7 63.3 ± 16.9 0.443 74.3 ± 20.9 60.0 ± 11.6 0.051
GGT, mean ± SD, mg/dL 22.3 ± 12.5 9 - 63 24.8 ± 10.6 21.5 ± 13.2 0.347 23.9 ± 10.7 21.5 ± 13.5 0.459 24.1 ± 9.9 21.2 ± 14.0 0.274
Albumin, mean ± SD, g/dL 4.47 ± 0.13 4.2 – 4.7 4.40 ± 0.16 4.49 ± 0.11 0.153 4.44 ± 0.17 4.49 ± 0.11 0.468 4.46 ± 0.17 4.48 ± 0.11 0.784
Globulin, mean ± SD, g/dL 2.96 ± 0.34 2.20 – 3.50 3.16 ± 0.27 2.91 ± 0.35 0.151 3.03 ± 0.36 2.93 ± 0.35 0.559 3.00 ± 0.34 2.94 ± 0.36 0.718
INR, mean ± SD, 0.98 ± 0.07 0.88 – 1.14 1.00 ± 0.11 0.97 ± 0.05 0.527 0.99 ± 0.07 0.97 ± 0.07 0.554 1.01 ± 0.88 0.96 ± 0.05 0.103
White blood cells, mean ± SD, /mm3 6,650 ± 1,329 4,880 – 9,100 7,168 ± 1,267 6,497 ± 1,345 0.333 6,803 ± 1,209 6,578 ± 1,416 0.721 6,773 ± 1,123 6,579 ± 1,470 0.752
Absolute neutrophil count, mean ± SD, /mm3 3,456 ± 1,132 1,819 – 6,825 4,302 ± 1,691 3,207 ± 823 0.055 3,762 ± 1,608 3,313 ± 863 0.399 3,748 ± 1,489 3,289 ± 890 0.372
Absolute lymphocyte count, mean ± SD /mm3 2,405 ± 565 1,249 – 3,583 2,222 ± 527 2,459 ± 579 0.423 2,339 ± 531 2,435 ± 595 0.719 2,345 ± 492 2,439 ± 618 0.718
Hemoglobin, mean ± SD, g/dL 13.5 ± 1.3 9.8 – 15.6 13.7 ± 1.1 13.5 ± 1.4 0.781 13.6 ± 1.0 13.5 ± 1.5 0.793 13.8 ± 1.0 13.4 ± 1.5 0.503
Platelet, mean ± SD, x103/mm3 234.5 ± 50.1 143 - 327 223.4 ± 70.2 237.8 ± 44.8 0.586 215.3 ± 55.7 243.5 ± 46.5 0.228 222.6 ± 55.6 241.2 ± 47.5 0.414
AFP, mean ± SD, ng/mL 2.71 ± 1.47 0.99 – 6.40 1.92 ± 0.62 2.95 ± 1.57 0.256 2.04 ± 0.73 3.03 ± 1.63 0.217 2.07 ± 0.68 3.08 ± 1.68 0.246
LS values, mean ± SD, kPa 7.12 ± 2.92 2.50 – 12.30 9.16 ± 3.00 6.59 ± 2.72 0.084 8.06 ± 2.56 6.77 ± 3.06 0.347 8.59 ± 2.83 6.37 ± 2.75 0.087
APRI, mean ± SD 0.35 ± 0.21 0.15 – 1.12 0.54 ± 0.37 0.30 ± 0.09 0.210 0.45 ± 0.33 0.30 ± 0.10 0.283 0.45 ± 0.31 0.30 ± 0.10 0.206
Abbreviations: CHB chronic hepatitis B, BMI body mass index, TB total bilirubin, DB direct bilirubin, AST aspartate aminotransferace, ALT alanine aminotransferase, ALP alkaline phosphatase, GGT gamma
glutamyltransferase, INR international normalized ratio, AFP α-fetoprotein, LS liver stiffness, APRI AST to platelet ratio index.
aSignificant liver inflammation (HAI necroinflammatory activity score ≥4 or Metavir necroinflammatory activity score ≥2).
bSignificant liver fibrosis (Metavir fibrosis score ≥2).












Table 2 Univariate analysis in prediction of significant liver histology
Parameters Significant liver inflammation Significant liver fibrosis Significant liver inflammation or fibrosis
n/N Percent p- value n/N Percent p-value n/N Percent p-value
Age≤ 40 years 3/7 42.9 0.160 4/7 57.1 0.107
Age≤ 42 years 4/8 50 0.039 5/8 62.5 0.032
Age≤ 50 years 4/11 36.4 0.155 5/11 45.5 0.181
BMI < 23 kg/m2 4/9 44.4 0.067 5/9 55.6 0.135
BMI < 24.5 kg/m2 5/13 38.5 0.049 7/13 53.8 0.052
BMI < 25 kg/m2 5/15 33.3 0.114 8/15 53.3 0.020
TB < 0.45 mg/dL 4/8 50 0.039
AST > 19 mg/dL 4/19 21.1 0.558
AST > 30 mg/dL 4/8 50 0.021
AST > 40 mg/dL 3/5 60 0.055
AST > 50 mg/dL 1/1 100 0.227
ALT > 30 mg/dL 4/12 33.3 0.218
ALT > 40 mg/dL 3/8 37.5 0.233
ALP > 78 mg/dL 4/5 80 0.003 4/5 80 0.039
Absolute neutrophil count > 4,300/mm3 3/4 75 0.024
LS values≥ 7.0 kPa 3/10 30 0.406 5/10 50 0.221
LS values≥ 8.5 kPa 3/5 60 0.233 5/8 62.5 0.072
LS values≥ 9.5 kPa 3/5 60 0.055 3/5 60 0.233
LS values≥ 11.5 kPa 2/2 100 0.043 2/2 100 0.121
HBV DNA levels > 4 log IU/mL 5/14 35.7 0.490
HBV DNA levels > 5 log IU/mL 5/11 45.5 0.181
HBV DNA levels > 5.5 log IU/mL 5/6 83.3 0.004
HBV DNA levels > 6 log IU/mL 3/4 75 0.077
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accurately predict advanced fibrosis especially stage 4
fibrosis or cirrhosis from meta-analysis studies, but
unfortunately, its accuracy as a predictor of significant
liver fibrosis (fibrosis stage ≥ 2) was just fair. These
studies demonstrate that LS values between fibrosis
stage 1 and 2 were similar [17-19]. LS values might be a
tool to predict advanced but not significant fibrosis, thus
it should not be used to guide treatment initiation
decisions except where LS values are high enough to
reflect advanced fibrosis or cirrhosis. Not surprisingly,
APRI was not associated with significant liver histology.
This correlated with the study by Degos et al. [20] where
APRI also had better accuracy in diagnosis of cirrhosis
than significant fibrosis [20]. In contrast, higher LSTable 3 Multivariate analysis in prediction of significant
liver fibrosis
Parameters Odds ratio p-value 95% confidence
interval
Age≤ 42 years 7.403 0.139 0.523-104.716
HBV DNA levels > 5.5
log IU/mL
28.012 0.022 1.631-481.240values tended to be associated with significant liver
inflammation. Moreover, LS values ≥ 11.5 kPa also
predicted significant liver inflammation in univariate
analysis. These findings are supported by previous
knowledge that hepatic inflammation is one of the
confounding factors in LS values [21,22]. Thus, LS
values as found in the patient group in this study might
really represent liver inflammation, not liver fibrosis.
Patients with significant liver inflammation had signifi-
cantly lower BMI and higher alkaline phosphatase than
another groups. However, these findings were not found in
other studies in HBeAg-negative CHB patients with varying
degrees of ALT [13-15]. Larger trials in the same fashion as
the present study are needed to clarify the influence of
these factors.
Nowadays, serum HBsAg level is considered to be a useful
test that can be used in many conditions in CHB patients. It
could predict HBV levels and liver-related diseases, and also
significant liver fibrosis in HBeAg-positive CHB patients
[23-26]. While it was also included in the present study, it
was not found to be associated with any significant
histology. Martinot-Peignoux et al. [27] also found the
same results with HBeAg-negative CHB patients with
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serum HBsAg level is not a potential tool in liver histology
assessment in HBeAg-negative CHB patients.
There is no predictor for significant liver histology in
the current study. Even if HBV DNA level was found to
predict significant liver fibrosis, it was not associated with
significant liver histology. An insignificant association with
significant liver inflammation and the small number
of patients with significant liver histology are possible
reasons to explain this finding.
The strength of the present study is the inclusion
criteria used. The authors gathered patients in a pro-
spective manner and strictly selected those that really
needed liver biopsy as recommended in guidelines,
though the result could also be applied in clinical
practice. Thus, the small number of total patients is a
limitation in the present study.
Conclusions
A serum HBV DNA level of > 5.5 log IU/ml was found
to predict significant liver fibrosis in treatment naïve
HBeAg-negative CHB patients that had indication for
liver biopsy as recommended by AASLD and APASL
guidelines.
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